SCHEMBL3744331

SCHEMBL3744331

CC(=O)CC(=O)C(C)(C)CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2203061 0.80 MAPT (0.31) GAA
SCHEMBL17494846 0.79
SCHEMBL769048 0.77 DGAT1 (0.37)
SCHEMBL161037 0.76 CYP2C9 (0.35)
SCHEMBL13041183 0.75
SCHEMBL2482629 0.75 MCL1 (0.31)
SCHEMBL2580539 0.75
SCHEMBL31637479 0.75 LMNA (0.31)
SCHEMBL3273808 0.74 MGAM (0.42) MGAMGAASIMGAM2
SCHEMBL1085871 0.73 MAPT (0.33) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735609-B2 Bryostatin analogues, synthetic methods and uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2014-05-27 US disclosed
US-8497385-B2 Bryostatin analogues, synthetic methods and uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2013-07-30 US disclosed
US-8497385-B2 Bryostatin analogues, synthetic methods and uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2013-07-30 US disclosed
US-20130123518-A1 Bryostatin Analogues, Synthetic Methods and Uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2013-05-16 US disclosed
US-20100280262-A1 BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2010-11-04 US disclosed
US-20100280262-A1 BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2010-11-04 US disclosed
US-20090270492-A1 BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2009-10-29 US disclosed
US-20090270492-A1 BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2009-10-29 US disclosed
WO-2009052507-A1 BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2009-04-23 WO disclosed
US-20070270485-A1 Byrostatin analogues, synthetic methods and uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2007-11-22 US disclosed
US-20070270485-A1 Byrostatin analogues, synthetic methods and uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2007-11-22 US disclosed
US-7256286-B2 Bryostatin analogues, synthetic methods and uses THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2007-08-14 US disclosed
US-20030220334-A1 Byrostatin analogues, synthetic methods and uses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-11-27 US disclosed
US-6624189-B2 Anticancer agents THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2003-09-23 US disclosed
WO-2003070719-A1 BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2003-08-28 WO disclosed
US-20020137789-A1 Byrostatin analogues, synthetic methods and uses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220334-A1 Byrostatin analogues, synthetic methods and uses BID, HASPIN, HPGDS MGAM 3931/4885GAA 4532/4885SI 1337/4885
US-20090270492-A1 BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES PBK, TK1, BAK1 MGAM 1477/4885GAA 3229/4885SI 1098/4885
US-20070270485-A1 Byrostatin analogues, synthetic methods and uses BID, HASPIN, HPGDS MGAM 3931/4885GAA 4532/4885SI 1337/4885
US-20020137789-A1 Byrostatin analogues, synthetic methods and uses BID, IGF2BP1, IGFBP4 MGAM 4034/4885GAA 4736/4885SI 1582/4885
US-20100280262-A1 BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES MCL1, PBK, BID MGAM 2142/4885GAA 3741/4885SI 782/4885
US-20130123518-A1 Bryostatin Analogues, Synthetic Methods and Uses MCL1, PBK, BID MGAM 2142/4885GAA 3741/4885SI 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.